Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/60—Salicylic acid; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/60—Salicylic acid; Derivatives thereof
  • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
  • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
  • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications

Definitions

• the invention relates to a medicament intended in particular for preventing or treating sexual dysfunctions in men or women.
• the invention relates in particular to obtaining a medicament capable of combating disorders of the physiological and / or anatomical response to sexual stimulation in humans.
• a drug contains, in combination, a purine and a non-steroidal anti-inflammatory agent.
• the erectile tissue of the penis is a spongy tissue capable of filling with blood.
• the arteries of the penis are under the dependence of the adrenergic tone which keeps them spasmed, so that no notable blood flow comes to fill the cavernous body.
• the erection nerves inhibit the adrenergic tone, releasing certain mediators promoting the dilation of the arteries of the penis, which leads to an accumulation of blood in the corpora cavernosa. The latter grows, while the increase in its internal pressure causes it to become rigid.
• vasodilation results in particular in the vasodilation of the blood vessels supplying the genitals. This vasodilation leads in particular to swelling and an erectile response of the clitoris, as well as vasocongestion of the vaginal wall with exudation of vaginal fluids. It is known that a fairly large proportion of men (between 10 and 50% depending on the populations studied and according to the age groups) suffer from permanent or temporary erectile dysfunction. These disorders can be of organic origin, in which case they require specific treatments adapted to each cause. But we also observe a majority of non-organic erectile dysfunctions, often of psychogenic origin; see for example Feldman H.A. et al, J. Urol. 151; 54-61 (1994).
• the physiological response to sexual stimulation can be altered temporarily, and sometimes durably, even without detectable organic cause.
• the most frequently observed disorders include the absence of sexual desire even after stimulation, the difficulty of obtaining an orgasm, the low intensity of sexual pleasure and the decrease in natural vaginal lubrication or even its absence. These disorders often result in a lack of interest in sexual activity. It is these disorders of the physiological and / or anatomical response to sexual stimulation that are called, in the present application, "female sexual dysfunctions". According to some estimates, the frequency of temporary or chronic sexual dysfunction in women is equivalent to that of erectile dysfunction in men; see for example Laumann EO, JAMA 281; 537-544 (1999).
• the physiology of erection and more generally the phenomenon of turgor of the erectile bodies (penis, clitoris), is a complex phenomenon which associates neuronal and vascular mediators.
• the erection is maintained by the relaxation of the arteries afferent to the cavernous body and the smooth muscles of this cavernous body.
• nitric oxide a complex phenomenon which associates neuronal and vascular mediators.
• NANC type nerve fibers non-adrenergic non-cholinergic
• Nitric oxide has been shown to stimulate the synthesis of cyclic guanosine monophosphate (or cGMP) which is the effective agent for muscle relaxation in the arteries.
• cGMP cyclic guanosine monophosphate
• nitrogen monoxide is the main physiological neurotransmitter involved by non-adrenergic and non-cholinergic peripheral neurons innervating the corpora cavernosa and its arteries, and that its release at the level of the effector synapse is an important factor in the 'induction of erection; see in particular BURNETT et al, Science 257: 401-403 (1992), and FAJFER et al, New Engl. J. Med. 326: 90-94 (1992).
• prostaglandins have a regulatory effect on the tone of the cavernous muscle, either by inducing vasolidation (prostaglandin 12, prostaglandin E2), or by causing vasoconstriction (prostaglandin F2alpha).
• purines also play an important role in vascular control of erection. They intervene in particular through specific receptors. It has been shown in rabbits that purines are capable of inducing relaxation of the corpora cavernosa; see WU H-Y et al. Int. J. Impotence Res. 5, 161-167 (1993). It has also been shown that intravenous injection of adenosine triphosphate induces erection in dogs; see TAKAHASHI Y. et al. Int. J. Impotence Res. 4, 27-34 (1992).
• the in vitro model used was that of the rabbit cavernous body isolated in organ chambers. A good response analogy has been shown with the human cavernous body. It is indeed in rabbits that the best correlations with the results obtained in humans have been observed; see for example Bush P.A., Aronson WJ, Buga GM, Rajfer J., Ignarro LJ J. Urol. 147-6); 1650-1655 (1992); Knispel HH., Goessel C, Bechman R, Urol. Res 20 (4); 253-257 (1992); Holmquist F, Hedlund H, Andersson KE, J. Physiol. (London) 449; 295-311 (1992); and Cellek S., Moncada S- Proc Natl Acad Sci USA, 94 (15); 8226-8231 (1997).
• Non-steroidal anti-inflammatory drugs have in common various properties, and in particular an activity of inhibition of cyclooxygenase. It was with a well-known non-steroidal anti-inflammatory drug, aspirin, that the above study was first conducted. The results have been confirmed with other NSAIDs, including salicylic acid, mefenamic acid and indomethacin.
• the combination of a purine activity and a non-steroidal anti-inflammatory agent activity makes it possible to obtain favorable results in the prevention and treatment of disorders of the physiological and anatomical response to sexual stimulation in humans ( man or woman), and therefore to combat said disorders, thanks to a synergistic effect.
• the subject of the invention is therefore a medicament combining a purine activity and an NSAID activity, and further comprising a pharmaceutical excipient or vehicle.
• the medicament of the invention generally contains at least one purine and at least one NSAID.
• purine is intended to mean purine bases, in particular adenine, nucleosides based on purine and in particular adenosine as well as the corresponding phosphates, in particular AMP, ADP and ATP, or still guanine, guanosine, GMP, GDP, GTP and their derivatives, in particular their pharmaceutically acceptable salts (for example adenosine or adenosine hydrochloride, or sodium salts of adenosine-phosphates). More generally, “purine” is also understood to mean any substance capable of acting on purine receptors (PI receptors sensitive to AMP and adenosine, or P2 receptors, sensitive to ADP and ATP). Such substances are known or can be sought according to known methods.
• a purine activity is an activity obtained by the presence of a purine as it has just been defined.
• Nonsteroidal anti-inflammatory drugs are a known class of anti-inflammatory drugs; see, for example, THE MERCK INDEX, 12 th edition, the content of which concerning NSAIDs (including data and references) is incorporated into this description by reference.
• NSAIDs have several properties in common, and in the first place an activity of inhibition of cyclooxygenase which gives them the capacity to inhibit the synthesis of prostaglandins.
• NSAIDs have other properties in common, and in particular the decoupling of oxidative phosphorylation, modifications of the intracellular movements of calcium ions, activation of the synthesis of inducible NO synthase, action on the nuclear factors kappa, etc.
• An NSAID activity is an activity obtained by the presence of a product having at least one of the properties common to NSAIDs.
• NSAIDs that can be used, there may be mentioned in particular:
• acetylsalicylic acid aspirin
• methyl salicylate methyl salicylate
• salicylic acid 2- (2-nitroxy) -butyl 2-acetoxybenzoate
• 2 2-nitroxymethyl
• - pyrazole derivatives such as phenylbutazone, tolmetin, antipyrine, noramidopyrine, dipyrone, oxyphenbutazone, azapropazone, bumadizone, clofezone, kébuzone, mofébutazone, proxifézone, pyrazinophenazone ;
• anthranilic acid derivatives such as mefenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, meclofenamic acid, etofenamic acid;
• - propionic acid derivatives such as: ibuprofen, ketoprofen, maproxen, fenoprofen, flurbiprofen, tiaprofenic acid, naproxen;
• NSAIDs selectively or preferentially inhibiting cyclooxygenase-2 (or Cox-2) such as rofecoxib, celecoxib or nabumetone;
• nitric oxide derived from NSAIDs in particular nitric esters and nitro and nitroso derivatives of NSAIDs such as those described in the patents and patent applications EP 0 670 825, US 5,700,947, WO 95/30641, US 5 703 073, US 6 043 232 and US 6 043 233, the content of which is incorporated into the present description by reference. It is of course possible to use all other NSAIDs (having the capacity to potentiate the action of purines) such as the NSAIDs described in THE MERCK INDEX, 12 th edition.
• derivatives are any products which are obtained by the modification of a chemical function or of an atom or group of atoms of an active product, and which have a physiological activity of same type as the active product.
• the derivatives of active products having acid functions can be in particular the salts (for example sodium salts or salts of other alkali metals, or amine salts such as piperazine or lysine salts), or esters formed by said acids with alcohols, or amides formed by these acids with amines; the derivatives of active products having amino functions are in particular the amides and the addition salts formed by these amines with acids; the derivatives of active products having alcohol functions are in particular the esters formed by said alcohols with acids.
• the medicament of the invention is used in such a way as to administer to the treated person effective doses which can be determined by simple routine experiments, using for example the tests which have just been mentioned. It should also be noted that the active doses of several purines are known. It is also easy to determine the effective doses using such tests. The doses of NSAIDs can be easily determined by routine tests, including tests such as those described below, on isolated rabbit organs.
• the subject of the invention is therefore the use in combination of a purine activity and an NSAID activity, in the preparation of a medicament intended for combating male or female sexual dysfunctions, including disorders of the physiological and / or anatomical response to sexual stimulation, and in particular to prevent or treat non-organic erectile dysfunctions.
• This medication can be administered to curative or preventive title, to subjects who need it, that is to say to people who have experienced or feared such disorders.
• active ingredients of a medicament obtained in accordance with the invention may be presented separately, each in an appropriate pharmaceutical form, and combined in the same package.
• the medicament in a single pharmaceutical form containing the two active ingredients, as well as optionally an appropriate pharmaceutical excipient.
• a compound having both a purine activity and an NSAID activity must be considered as constituting on its own a combination having the two types of activity, and can therefore be used in accordance with the invention as active ingredient unique.
• a purine and an NSAID can be combined by establishing a chemical bond between the two molecules.
• One can in particular amidify an amino function of the purine base with an acid group present in an NSAID such as for example acetylsalicylic acid or mefenamic acid.
• An amidification product can thus be obtained which has both purine activity and NSAID activity.
• A is the rest of the molecule of an NSAID
• B is the rest of a purine
• X represents either a covalent bond between A and B , or a spacer arm connecting at least one remainder A to at least one remainder B
• m is an integer which can range from 1 to 3
• n is an integer which can range from 1 to 3
• p represents zero or an integer at most equal to the largest of the numbers m and n.
• the products of formula I can be used in the form of salts, in particular in the form of alkali metal salts such as sodium or potassium salts; these salts are for example those of phosphate groups, if they are present, phenolic groups (case of salicylic acid), etc.
• the products of formula I can also be used, where appropriate, in the form of addition salts (for example in the form of the hydrochloride) when these products contain an amino group.
• the bonds between the spacer arm and the remains A and B are covalent bonds.
• A can represent in particular the acyl residue of an NSAID having a carboxylic group (the NSAID therefore has the formula A-OH) and B can represent the residue of a purine-based nucleoside or nucleotide linked to X , or connected to A (in the absence of a spacer arm), via the nitrogen of a primary amine of the purine base and / or via the oxygen of a hydroxyl group of said purine-based nucleoside or nucleotide; for example one or more groups A or AX- can be linked to B via the oxygen of the primary alcohol of said nucleoside and / or via the oxygen of at least one secondary alcohol of said nucleotide .
• the purine from which B derives obviously has the formula BH.
• said nucleoside or nucleotide is in particular a ribonucleoside or ribonucleotide.
• the purine can be chosen from adenosine, guanosine and inosine, as well as the corresponding 5 '-monophosphates, -diphosphates and -triphosphates.
• the spacer arms may in particular be bivalent residues of bi-functional aliphatic compounds (that is to say compounds having reactive functional groups at each of their ends, each making it possible to form covalent bonds with A and with B).
• These compounds may for example be compounds which have both an amino group and a carboxylic (or thiocarboxylic) group, or alternatively compounds which have both an amino group and a hydroxyl group.
• group X (disregarding its end functional groups) represents in particular a divalent aliphatic group possibly interrupted by one or more heteroatoms - O - or - S - or by one or more heteroatomic groups - NH - or - CO - NH -.
• the spacing agents that is to say the compounds capable of giving, after reaction with purine and the NSAID, products of formula I in which A and B are linked by spacer arms, are for example alpha acids -, beta- or gamma-amino alkanecarboxylic acids, in particular natural alpha-amino acids such as glycine, alanine, valine or leucine, or even peptides, in particular dipeptides or tripeptides.
• the spacing agents can also be hydroxycarboxylic acids such as lactic, glycolic acids, aldonic acids (gluconic, mannonic, galactonic, ribonic, arabinonic, xylonic and erythronic) and the corresponding lactones or dilactones (for example lactide, glycolide, delta-glucolonactone, delta-valeronactone), or aldaric acids.
• hydroxycarboxylic acids such as lactic, glycolic acids, aldonic acids (gluconic, mannonic, galactonic, ribonic, arabinonic, xylonic and erythronic) and the corresponding lactones or dilactones (for example lactide, glycolide, delta-glucolonactone, delta-valeronactone), or aldaric acids.
• the functional groups optionally present on the spacer arm and not involved in the binding with an element A or B can be used to graft other residues A and / or B so as to obtain compounds of formula I for which m and / or n are greater than 1. This is the case, for example, of the hydroxyl groups of the hydroxy acids, of the second carboxylic group of the amino acids dicarboxylic acids, of the second amino group of the amino diamines, of the hydroxyl group of the hydroxy amino acids, etc.
• a carboxylic compound (NSAID or spacer agent) can be reacted in the form of a carboxylic acid (or thiocarboxylic) halide, or in the form of a mixed anhydride, or in the form of an activated ester, for example a p-nitrophenyl ester.
• the acid can also be activated using a coupling agent such as dicyclohexylcarbodiimide.
• the compounds of formula I include residues of nucleosides or nucleotides, they can be prepared using in particular the methods known in the chemistry of nucleic acids, described for example in the work by Kochetkoc and
• the -NH 2 groups can be protected by carbobenzoxy, phthaloyl, t-butoxycarbonyl, trifluoroacetyl, toluenesulfonyl groups;
• the carboxylic groups can be protected in the form of benzyl esters, tetrahydropyranyl esters or t-butyl esters;
• the alcohols can be protected in the form of esters (for example acetates), in the form of tetrahydropyranyl ethers, of benzyl ethers or of trityl ethers, or also in the form of acetals (including under the form of acetonides in the case of vicinal glycols).
• the phosphating or dephosphating reactions of the primary alcohol of the nucleotides or nucleosides can be carried out using natural enzymes (for example phosphatases, phosphokinases).
• natural enzymes for example phosphatases, phosphokinases.
• A represents in particular the acyl residue of an NSAID having a carboxylic group, the bond with B taking place for example by the formation of an amide or of an ester with an amino or alcohol function, respectively, of the purine of which the formula is BH.
• the products of formula I or la generally have an improved gastric tolerance, compared to the NSAID from which they are derived.
• the products of formula I there may be mentioned in particular the amidation product of AMP by salicylic acid or acetylsalicylic acid, and the amidation product of adenosine with salicylic acid.
• the medicament obtained in accordance with the invention can be administered by oral, sublingual, nasal, pulmonary, vaginal, rectal or transdermal route, or also by intracavernous injection.
• oral administration in particular in the form of capsules, oral solutions or emulsions, powders, gels, granules, tablets or tablets
• nasal route for example solutions to be administered in the form of drops or sprays
• pulmonary way solutions in pressurized bottle for aerosols
• rectal way suppositories
• cutaneous way for example ointments or transdermal devices, also called patches or patches
• transmucosal route for example by the sublingual route (solutions in a pressurized bottle, or tablets with oral disintegration) or by the vaginal route (in particular gynecological creams or ova), or even by the intracavernous route (suspensions or injectable solutions) .
• the medicament of the invention makes it possible to obtain favorable results in men suffering from transient erectile dysfunctions, and also in subjects suffering from chronic erectile dysfunctions.
• improvements can be noted in particular for at least one of the following disorders: loss or reduction of sexual desire, absence of orgasm or difficulty in obtaining orgasm, vaginal dryness, reduction in the intensity of sexual pleasure, etc.
• the medicament obtained in accordance with the invention can be used either for long periods in the case of chronic erectile dysfunctions (for example cures lasting several weeks, several times a year), or in episodic cures in the treatment of temporary erectile dysfunctions and / or recent, or again on an ad hoc basis.
• a medicament can be prepared for example in a pharmaceutical form allowing the administration of 50 to 1000 mg of AMP in one or two doses, or an equivalent dose of another purine, and also allowing the administration of a a sufficient dose of NSAIDs, for example a dose of 50 to 500 mg per day of aspirin, in one or two doses, or an equivalent dose of another NSAID.
• a dose of 50 to 1000 mg of AMP for example, a dose of 50 to 1000 mg of AMP and
• aspirin 50 to 500 mg per day of aspirin, in adults, for a treatment which should last from 2 to 4 weeks.
• AMP can be replaced in particular by equivalent amounts of ATP.
• a dose of purine equivalent to a given dose of AMP is for example a dose of purine capable of inducing relaxation of the smooth muscles of the corpora cavernosa (previously contracted with phenylephrine), isolated from rabbits, in an organ chamber, this relaxation being comparable to that obtained with said given dose of AMP, in a test using the known techniques described in particular by HOLMQUIST et al, J. Urol.
• a dose of NSAID equivalent to a given dose of aspirin is for example a dose which, in combination with a purine, is capable of inducing relaxation of the smooth muscles of the corpora cavernosa which is comparable to the relaxation obtained with said dose of aspirin combined with the same purine, in a test using one of the techniques just mentioned.
• the invention also relates to a method of preventing or treating male or female sexual dysfunctions, in which a medicament as defined above is administered.
• the invention also relates to a non-therapeutic method for increasing sexual desire and / or sexual capacities and / or promoting sexual activity and / or improving the intensity of the sexual pleasure and / or favor the achievement of satisfactory sexual intercourse, in the people who wish it, although not suffering from sexual dysfunctions as defined above.
• This method comprises administering to such persons a purine and an NSAID (or a composition combining a purine activity and an NSAID activity), in particular AMP and aspirin, for example between two hours and one half an hour before a planned sexual activity.
• the doses administered can be chosen from the dose ranges indicated above.
• AMP can be replaced by an equivalent amount of ATP
• aspirin can be replaced by an equivalent dose of mefenamic acid, salicylic acid, diclofenac, dibuprofen, naproxen, sulindac or indometacin.
• the objective of this study is the search for an effect of purines (AMP and ATP) on the relaxation of the corpora cavernosa after a pre-contraction to phenylephrine and the search for a possible modification of this effect of purines by aspirin.
• the study was done in male and female rabbits.
• AMP (10 " 3M) induces relaxation of 20%, reaching 36% in the presence of aspirin.
• ATP (10 " 3M) seems to cause slightly greater relaxation , by 31%, reaching 50% in the presence of aspirin.
• aspirin amplifies the relaxing response of the purines studied (AMP or ATP). This amplification is by a factor ranging from 1.5 to 2.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Rheumatology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Pain & Pain Management (AREA)
• Gynecology & Obstetrics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=8853401

Family Applications (2)

Family Applications After (1)

Country Status (13)

Families Citing this family (9)

Family Cites Families (4)

• 2000
  • 2000-08-08 FR FR0010435A patent/FR2812812B1/fr not_active Expired - Fee Related
• 2001
  • 2001-08-08 BR BR0112830-2A patent/BR0112830A/pt not_active IP Right Cessation
  • 2001-08-08 AU AU2001284125A patent/AU2001284125A1/en not_active Abandoned
  • 2001-08-08 CN CNA018170315A patent/CN1468104A/zh active Pending
  • 2001-08-08 CA CA002420066A patent/CA2420066A1/fr not_active Abandoned
  • 2001-08-08 BR BR0112908-2A patent/BR0112908A/pt not_active IP Right Cessation
  • 2001-08-08 JP JP2002517071A patent/JP2004505921A/ja active Pending
  • 2001-08-08 RU RU2003105601/15A patent/RU2003105601A/ru not_active Application Discontinuation
  • 2001-08-08 IL IL15421601A patent/IL154216A0/xx unknown
  • 2001-08-08 IL IL15421501A patent/IL154215A0/xx unknown
  • 2001-08-08 AU AU2001284126A patent/AU2001284126A1/en not_active Abandoned
  • 2001-08-08 EP EP01963079A patent/EP1309331A2/fr not_active Withdrawn
  • 2001-08-08 RU RU2003105600/15A patent/RU2003105600A/ru not_active Application Discontinuation
  • 2001-08-08 CA CA002419042A patent/CA2419042A1/fr not_active Abandoned
  • 2001-08-08 NZ NZ523906A patent/NZ523906A/en unknown
  • 2001-08-08 ZA ZA200300967A patent/ZA200300967B/en unknown
  • 2001-08-08 WO PCT/FR2001/002580 patent/WO2002011735A2/fr active IP Right Grant
  • 2001-08-08 EP EP01963080A patent/EP1311273A2/fr not_active Withdrawn
  • 2001-08-08 ZA ZA200300966A patent/ZA200300966B/en unknown
  • 2001-08-08 WO PCT/FR2001/002579 patent/WO2002011665A2/fr not_active Application Discontinuation
  • 2001-08-08 JP JP2002517003A patent/JP2004505897A/ja active Pending
  • 2001-08-08 CN CNA018170404A patent/CN1496265A/zh active Pending
• 2003
  • 2003-02-07 US US10/360,280 patent/US20030139368A1/en not_active Abandoned
  • 2003-02-07 US US10/360,354 patent/US20030139371A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events